Quick Answer
MAXCYTE, INC. reported Stockholders Equity of $171.49 million for the year ending 2025.
- MAXCYTE, INC. showed a decrease of -16.9% in Stockholders Equity from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $11.09 million | Q2 2020: $37.21 million | Q3 2020: $34.99 million | Q1 2021: $81.29 million | Q2 2021: $78.82 million | Q3 2021: $264.12 million | Q1 2022: $262.18 million | Q2 2022: $257.22 million | Q3 2022: $254.43 million | Q1 2023: $247.82 million | Q2 2023: $240.98 million | Q3 2023: $233.38 million | Q1 2024: $226.36 million | Q2 2024: $221.26 million | Q3 2024: $213.30 million | Q1 2025: $199.41 million | Q2 2025: $190.72 million | Q3 2025: $180.28 million.
- Over the full 8 years of available data (2018 to 2025), MAXCYTE, INC.'s Stockholders Equity has grown by 1,296.3%.
- Historical annual values: Fiscal year 2025: $171.49 million | Fiscal year 2024: $206.25 million | Fiscal year 2023: $232.17 million | Fiscal year 2022: $253.97 million | Fiscal year 2021: $262.90 million | Fiscal year 2020: $33.23 million | Fiscal year 2019: $13.60 million | Fiscal year 2018: $12.28 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: